The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.
作者信息
Burger David M, Schwietert H Reinier, Colbers E P H, Becker Mark
出版信息
Br J Clin Pharmacol. 2006 Aug;62(2):250-2. doi: 10.1111/j.1365-2125.2006.02635.x.
Abstract
摘要
相似文献
1
The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.
Br J Clin Pharmacol. 2006 Aug;62(2):250-2. doi: 10.1111/j.1365-2125.2006.02635.x.
2
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
Br J Clin Pharmacol. 2008 Apr;65(4):548-57. doi: 10.1111/j.1365-2125.2007.03039.x. Epub 2007 Oct 8.
3
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Br J Clin Pharmacol. 2000 Aug;50(2):108-15. doi: 10.1046/j.1365-2125.2000.00238.x.
4
Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.
Drug Metab Dispos. 2004 Dec;32(12):1462-7. doi: 10.1124/dmd.104.001743. Epub 2004 Sep 24.
5
Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.
Br J Clin Pharmacol. 2009 Nov;68(5):682-9. doi: 10.1111/j.1365-2125.2009.03499.x.
6
CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.
J Acquir Immune Defic Syndr. 2010 Jul;54(3):285-9. doi: 10.1097/QAI.0b013e3181bf648a.
7
Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study.
J Clin Pharmacol. 2009 Mar;49(3):291-300. doi: 10.1177/0091270008329551.
8
Dose of proton pump inhibitors and the CYP2C19 genotype.
Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):1. doi: 10.1111/j.1742-7843.2004.pto950101.x.
9
[Progress in the studies on the CYP2C19 polymorphism].
Sheng Li Ke Xue Jin Zhan. 2003 Apr;34(2):171-4.
10
Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?
Pharmacogenetics. 2003 Jul;13(7):383-8. doi: 10.1097/01.fpc.0000054098.48725.88.
引用本文的文献
1
Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.
OMICS. 2013 Oct;17(10):519-26. doi: 10.1089/omi.2012.0068. Epub 2013 Sep 9.
2
Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.
Br J Clin Pharmacol. 2009 Nov;68(5):682-9. doi: 10.1111/j.1365-2125.2009.03499.x.
3
CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.
J Acquir Immune Defic Syndr. 2010 Jul;54(3):285-9. doi: 10.1097/QAI.0b013e3181bf648a.
4
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
Br J Clin Pharmacol. 2008 Apr;65(4):548-57. doi: 10.1111/j.1365-2125.2007.03039.x. Epub 2007 Oct 8.
本文引用的文献
1
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67. doi: 10.2133/dmpk.20.153.
2
Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.
Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95. doi: 10.2133/dmpk.19.83.
3
Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.
Drug Metab Dispos. 2004 Dec;32(12):1462-7. doi: 10.1124/dmd.104.001743. Epub 2004 Sep 24.
4
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
Ther Drug Monit. 2003 Jun;25(3):393-9. doi: 10.1097/00007691-200306000-00023.
5
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.
Ther Drug Monit. 2003 Feb;25(1):73-80. doi: 10.1097/00007691-200302000-00011.
6
Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
AIDS. 2002 Jul 5;16(10):1331-40. doi: 10.1097/00002030-200207050-00004.
7
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Br J Clin Pharmacol. 2000 Aug;50(2):108-15. doi: 10.1046/j.1365-2125.2000.00238.x.
Zotero 插件